Abstract
Abstract Studies of our group have previously assessed the therapeutic efficacy in a PDAC mouse model of the combined genetic elimination of EGFR and RAF1, two main targets of the KRAS molecular pathway. Specifically, our results illustrated that, PDACs are composed of at least two distinct tumor cell populations based on their response (regression or non-response) to the combined elimination of EGFR and c-Raf both in vivo and in vitro that can be distinguished by a different expression profile (Blasco et al., Cancer Cell, 2019). We have further studied the nature of this heterogeneity that interferes with the efficacy of this therapeutic strategy by OMICs and we have identified targetable molecular pathways as promising therapeutic approaches that we are currently validating. Citation Format: Vasiliki Liaki. Exploring therapeutic strategies against pancreatic ductal adenocarcinoma (PDAC) [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-086.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
